Article

Novel therapeutic targets in NSCLC resistance to Erlotinib

2017-01-01

Abstract excerpt

Approximately 10% of non-small cell lung cancers (NSCLCs) have an activating mutation within the kinase domain of epidermal growth factor receptor (EGFR). Competitive tyrosine kinase inhibitors (TKIs), such as Erlotinib and Gefitinib, have been developed to therapeutically exploit this. These compounds have shown excellent clinical responses in approximately 77% of patients with EGFR-mutant driven lung cancer. How...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b33030a8-ad2d-59ae-862f-e59edca5946a
DOI: 10.25560/50699

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Novel therapeutic targets in NSCLC resistance to ErlotinibDOI 10.25560/50699Read

Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of ResistanceSemantic proximity Read

EGFR Mutation Subtypes Modulate Distinct Metabolic Profiles and Clinical Outcomes in Lung Cancer: A Retrospective AnalysisSemantic proximity Read

Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.Semantic proximity Read

Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy.Semantic proximity Read

Multi-omic profiling of tyrosine kinase inhibitor-resistant K562 cells suggests metabolic reprogramming to promote cell survivalSemantic proximity Read

mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer.Semantic proximity Read

Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis.Semantic proximity Read

Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.Semantic proximity Read

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI.Semantic proximity Read

Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.Semantic proximity Read

NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC.Semantic proximity Read

Metabolic rewiring drives resistance to targeted cancer therapySemantic proximity Read